Michael Gamcsik

Has grant

Associate Professor

North Carolina State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Michael Gamcsik is an Associate Professor at North Carolina State University in the United States. His research focuses on mass spectrometry imaging and metabolic processes in cancer, particularly in relation to glycine uptake and glutathione biosynthesis. Recent publications include works on cell proliferation assays in varying oxygen environments and innovative techniques for mapping metabolic conversions in tumors.

Recent Grants

Grant: Close

Mapping Functional Heterogeneity in Tissue

Open Date: 2019-09-15

Close Date: 2021-08-31

Grant: Close

High-Throughput Screening Under Static or Dynamic Hypoxia

Open Date: 2016-07-13

Close Date: 2019-05-31

Grant: Close

PDAC-on-a-Chip for Selection of Aggressive, Therapy-Resistant Tumor Cells

Open Date: 2012-08-01

Close Date: 2014-07-31

Grant: Close

Spectroscopic Imaging of Antioxidant Metabolism in the Brain

Open Date: 2007-09-01

Close Date: 2010-08-31

Grant: Close

Noninvasive Monitoring Glutathione Metabolism in Tumors

Open Date: 2006-03-17

Close Date: 2013-01-31

Articles (5)

Year:

2025

Increased levels of glutathione (GSH) and related antioxidant processes are thought to predict breast tumor aggressiveness and therapy response. In our 2012 review of 21 studies, we found that most patient breast tumors exhibited increased GSH levels compared to peritumoral tissue. However, there was no clear relationship between GSH levels and histological grade, clinical stage, or patient outcome. For this update, database searches found 59 studies that reported the levels of any of 10 metabolites, including GSH, cysteine (Cys), ascorbate (Asc), and taurine (Tau), in breast tumor tissues. The increase in the number of studies profiling tumor metabolites is mainly due to the use of an array of relatively new metabolomics technologies. However, many of these metabolomics methods are not designed to prevent sample oxidation during tissue procurement and processing. Despite this, these recent studies confirm that the levels of most of the antioxidants or related metabolites are increased in patient breast tumor tissues compared to normal tissues. In addition, poor patient outcomes are often associated with tumor tissues with higher GSH and lower Tau levels. GSH levels also increase with histological grade. There are no clear trends in the relationship between any of the antioxidant levels and tumor stage or genetically defined subtypes. Clearer trends may emerge with more uniform tissue sampling, preparation, and assay procedures. In addition, the increased use of spatial metabolomics methods may help to clarify the relationship between antioxidant levels and clinical markers.

Year:

2025

Year:

2023

Year:

2022

Year:

2022